OVERVIEW

Advances In™ Multiple Myeloma (MM): Using Proteasome Inhibitors Throughout the Disease Continuum is organized by Physicians' Education Resource, LLC (PER).

Release Date: December 23, 2019
Expiration Date: December 23, 2020

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
Therapeutic options in patients with multiple myeloma (MM) have expanded rapidly with enhanced understanding of tumor biology and of the heterogeneous nature of the disease; these include the clinical development of proteasome inhibitors (PIs). Several PIs are approved for the treatment of MM, and in addition to the currently approved agents, trials are ongoing for emerging PIs in the frontline, relapsed/refractory, and maintenance therapy settings. Different combination strategies that incorporate PIs are available as treatment options, and each is associated with different adverse-event profiles and considerations for tolerability. As new information accumulates, appropriate clinical application of PIs within the changing treatment landscape becomes increasingly more challenging.

This Advances in™ Multiple Myeloma program will help clinicians meet the challenge of acquiring this knowledge by featuring a series of video interviews with Sagar Lonial, MD, an expert on MM. He will highlight key characteristics that help differentiate among PIs that are approved for the frontline and relapsed/refractory treatment settings for MM, as well as among PIs that are under clinical development.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Differentiate between proteasome inhibitor-based combination strategies for the treatment of MM.
• Identify patient and disease characteristics that influence the choice of appropriate proteasome inhibitor treatment strategies for MM.
• Formulate strategies to proactively identify and mitigate adverse events associated with proteasome inhibitors.
• Evaluate emerging data regarding the use of proteasome inhibitors and combination strategies for the treatment of MM.

Benefits of Participating:
• Increase knowledge and competence in the best-practice use of PIs for patients with MM
• Learn strategies to optimally manage treatment-related adverse events while treating patients with PI-based therapies
• Build confidence in your knowledge of how to integrate patient and disease characteristics into the clinical decision-making process for the use of PI-based therapies
• Improve knowledge of current clinical data on the use of PIs for the treatment of MM